EGFR and interstitial lung disease: Although furmonertinib is generally well-tolerated and no severe drug-related interstitial lung disease (ILD) has been reported in the literature to date, we present a case of furmonertinib-induced ILD in a 71-year-old woman with EGFR-mutated lung adenocarcinoma (LUAD).